CEL-SCI Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CVM research report →
Price Chart
About the company
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology.
- CEO
- Geert R. Kersten
- IPO
- 1983
- Employees
- 43
- HQ
- Vienna, VA, US
Get TickerSpark's AI analysis on CVM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.28M
- P/E
- -0.47
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.34
- EV/EBITDA
- -1.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -202.14%
- ROIC
- -117.44%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-15,886,977-300.3%
- Op Income
- $-24,809,736
- Net Income
- $-25,411,055+5.6%
- EPS
- $-6.27+53.6%
- OCF Growth
- +9.0%
- FCF Growth
- +9.2%
- 52W High
- $7.80
- 52W Low
- $0.89
- 50D MA
- $1.66
- 200D MA
- $2.22
- Beta
- 0.62
- RSI (14)
- 48
- Avg Volume
- 218.75K
No earnings-call transcripts are available for CVM yet.
- Free Float
- 93.1%
- Shares Outstanding
- 17.59M
- Float Shares
- 16.37M
of shares held by institutions
40 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 566.33K | ▲ 23.25K |
| Renaissance Technologies LLC | 470.87K | ▼ 101.59K |
| Vanguard Group Inc | 285.12K | ▼ 7.45K |
| Citadel Advisors LLC | 198.50K | ▲ 198.50K |
| Geode Capital Management, LLC | 130.17K | ▲ 41.97K |
| Mai Capital Management | 109.28K | ▲ 1.00K |
| Vanguard Fiduciary Trust Co | 102.76K | ▲ 53.72K |
| Commonwealth Equity Services, LLC | 55.41K | ▲ 3.98K |
| Jane Street Group, LLC | 44.84K | ▲ 8.39K |
| Osaic Holdings, Inc. | 44.29K | ▲ 11.51K |
| Blackrock, Inc. | 43.21K | ▼ 51 |
| Bank Of America Corp | 40.92K | ▼ 81 |
Held by 23 ETFs
Biggest fund positions in CVM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | TALOR EYAL | other | 1,165 |
| Sep 30, 26 | PRICHEP PATRICIA B | other | 2,082 |
| Sep 30, 26 | KERSTEN GEERT R | other | 2,621 |
| Aug 25, 26 | KERSTEN GEERT R | buy | 100,000 |
| Aug 14, 26 | Watson Robert Eugene | other | 110,000 |
| Aug 14, 26 | BAILLAVOINE BRUNO JEAN-MARIE | other | 110,000 |
| Aug 14, 26 | CIPRIANO JOHN | other | 80,000 |
| Aug 14, 26 | TALOR EYAL | other | 250,000 |
| Aug 14, 26 | PRICHEP PATRICIA B | other | 225,000 |
| Aug 14, 26 | KERSTEN GEERT R | other | 300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CVM coverage
Recent articles, reports, and earnings notes.
No research on CVM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CVM report →CEL-SCI's Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
businesswire.com · Nov 20
CEL-SCI's Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
businesswire.com · Nov 10
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
businesswire.com · Oct 26
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
businesswire.com · Sep 15
CEL-SCI Reports Fiscal Third Quarter 2026 Results
businesswire.com · Aug 17
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
businesswire.com · Aug 4
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
businesswire.com · Jul 30
CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer
businesswire.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.